Physician Guide
Non-Opioid Intrathecal Therapy Pain Medication
IMPORTANT SAFETY INFORMATION
WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS
PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.

Thank You

Thank you for your submission. Your request for more information about PRIALT has been sent.

 

INDICATION
PRIALT® (ziconotide) intrathecal infusion (25mcg/mL, 100mcg/mL) is indicated for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine.

©2016 Jazz Pharmaceuticals plc or its subsidiaries.
US-PRI-0186 REV 0916
Last updated on: June 20, 2017
SHOW MAIN MENU
SHOW SUB MENU